Abstract：To understand the resistance and distribution characteristics of carbapenemase-producing
Enterobacteriaceae bacteria in 2016—2017 in the western part of China, and provide the basis for clinical antiinfection
treatment. Methods Using a fully automated microbiological analyzer, drug susceptibility testing was
performed on clinical isolates in 10 hospitals in the western region according to a unified protocol. The KB paper method was used for supplementation. The results were based on the 2017 CLSI standard. The WHONET 5.6 software
was used to make the statistical analysis. Results A total of 1,845 clinically isolated CRE strains were collected
from 10 hospitals in 2016 and 2017. The top 5 isolates of Enterobacteriaceae were 953 Klebsiella pneumoniae (52%,
953/1845), E. coli 266 strains (14%, 266/1845), Enterobacter cloacae 264 (14%, 264/1845), Citrobacter freundii 69
(4%, 69/1845) and Proteus mirabilis 62 (3%, 62/1845). Drug susceptibility test results showed that the CRE strains
were highly resistant to most clinically used antibiotics, except the resistance rates to tigecycline and polymyxin B
were 5% and 8%, and the resistance rate to amikacin was 32.2%, and the resistance rate to other antimicrobial agents
were mostly 80%~97%. The resistance rates of CRE children's isolates to amikacin, ciprofloxacin, polymyxin, and
tigecycline were lower than those of the adult isolates. Conclusion CRE strains were highly resistant to most
commonly used antibiotics in clinical practice. The monitoring of bacterial resistance, hospitalization and the effective
control of antibiotics should be strengthened to prevent the spread of CRE strains in hospitals.
